In February 2011, Pfizer announced it would be closing its entire research and development (R&D) facility in Sandwich, Kent, with the loss of 2400 jobs. *Nature* (1 February 2011) commented that UK governments had repeatedly been warned that the country is perceived as being unfavourable to medical research, although Pfizer claimed its decision was not made on those grounds. The Academy of Medical Sciences recently produced a report expressing concern that it is exceptionally difficult to get ethical approval for clinical trials in the UK (Academy of Medical Sciences, [@r1]). It made recommendations for reform of the 'much maligned' European legislation on the matter.

While the number of clinical trials approved in the UK has not dropped significantly in recent years, the UK's global share of patients in trials plummeted from 6% in 2004 to just 2.5% in 2008. It takes an average of 621 days in the UK from the award of a research grant through to the first patient entering a trial, compared with 30--60 days in Canada, because of the complexities of the current system. The chair of the Academy working group that produced the report, Michael Rawlins, highlighting the difficulty getting permission for a funded trial to be enacted, commented: 'at the moment nobody knows half the time where to go and what to do' (quoted in the same issue of *Nature*).

In light of the problems encountered here, and to a similar degree in the USA, it is hardly surprising that 'Big Pharma' has turned to low- and middle-income countries to conduct trials. The attraction of countries where legislation on ethical constraints is rather less rigorous than in Europe or North America was discussed in a special report from the Reuters news agency ([@r2]). In 2008, a total of 78% of all participants in trials to support drug applications submitted to the US Food and Drug Administration (FDA) were enrolled at foreign sites. In Europe, 61% of patients in trials submitted to the European Medicines Agency between 2005 and 2009 came from low- and middle-income countries. A further 11% were from Eastern European countries that had recently joined the European Union.

Here, we present three papers on this contentious subject. The first presents an overview of the challenges from an African perspective. Akwasi Osei is from Ghana, and he debates both the positive and the negative implications of what has become a rapidly developing trend. Second, we learn about the role played by contract research organisations, in a piece by Mariëtte van Huijstee and Nuria Homedes. This is an important article, shedding light on the little-known phenomenon of 'contracting out' clinical trials to organisations over which there is little formal control. Finally, we gain a fascinating insight into the growth of the manufacture and marketing of generic drugs in India, from Anita Kotwani.
